GW Pharma (GWPH) Posts Smaller Q3 Loss

GW Pharma (NASDAQ: GWPH) reported Q3 EPS of ($1.26), $1.41 better than the analyst estimate of ($2.67). Revenue for the quarter came in at $3.46 million versus the consensus estimate of $2.94 million.

Cash and cash equivalents at 30 June 2018 of £334.0 million ($440.2 million) compared to £241.2 million as at 30 September 2017

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15